Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31730690 | 0.89 | DGAT1 (0.35) | DGAT1NPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31730686 | 0.88 | KMT2A (0.35) | DGAT1NPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16427447 | 0.87 | DGAT1 (0.37) | DGAT1NPC1KMT2APKMMEN1 | |
| SCHEMBL31381599 | 0.87 | DGAT1 (0.37) | DGAT1NPC1KMT2APKMMEN1 | |
| SCHEMBL2144593 | 0.85 | NPC1 (0.32) | NPC1TDP1 | |
| SCHEMBL31730788 | 0.84 | DGAT1 (0.34) | DGAT1NPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31730412 | 0.84 | DGAT1 (0.34) | DGAT1NPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL21904215 | 0.83 | CALCRL (0.34) | DGAT1PKMBACE1ANPEP | |
| SCHEMBL2265675 | 0.81 | TP53 (0.38) | NPC1MAPTALDH1A1KMT2APKM | |
| SCHEMBL2541904 | 0.81 | PKM (0.41) | DGAT1MAPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105308039-B | Indolin-2-one or pyrrolo-pyridine/pyrimid-2-one derivative | 豪夫迈·罗氏有限公司 | 2019-06-28 | — | — | CN | disclosed |
| EP-3010914-B1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9616053-B2 | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2895476-B1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-06-22 | — | — | EP | disclosed |
| EP-3010914-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-04-07 | — | — | US | disclosed |
| CN-105308039-A | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives | HOFFMANN LA ROCHE | 2016-02-03 | — | — | CN | disclosed |
| US-9221816-B2 | 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders | HOFFMANN LA-ROCHE INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2895476-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014040969-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HTR2C, OPRD1, DRD3 | DGAT1 3063/4885NPC1 1856/4885MAPT 1079/4885 |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HCRTR2, TPH2, CNR2 | DGAT1 3274/4885NPC1 1757/4885MAPT 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.